Search Videos and More
News
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma (aRMS), an aggressive childhood cancer with poor survival and few targeted treatment options, to identify new treatment vulnerabilities. Using a network-based analysis of large functional genomic datasets, they found that aRMS cells depend on CDK8, a protein involved in controlling gene activity.
News
Dana-Farber Research News 07.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 16 - 30.
News
Three-Drug Treatment Shows Promise for Patients with Rare Blood Cancer BPDCN
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.
News
The RAS Moment for Pancreatic Cancer Research
Dana-Farber investigators are at the forefront of a new era in RAS therapeutics for pancreatic cancer research
News
Rapid Epigenetic Test Could Speed Diagnostics for Acute Leukemias
Acute leukemias are life-threatening blood conditions that need urgent treatment. Approved targeted therapies such as BCL2, IDH, and menin inhibitors have expanded treatment options for certain patients, but determining if a given patient might benefit from one of these treatments can take time. Doctors need to order multiple complex diagnostic workups that can take days or even weeks to complete.
News
Dana-Farber Research News 07.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.
Video
ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.
Video
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
Video
2026 ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Video
ASCO26: David Reardon, MD, Glioblastoma Vaccine
Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.